TISSUE PROTEOMICS AND CUSTOM-MADE TRANSCRIPTOMIC ANALYSIS TOOL TO IDENTIFY PROGNOSTIC BIOMARKERS IN PROSTATE CANCER

SABATER, AGUSTINA; LAVIGNOLLE, ROSARIO; COTIGNOLA, JAVIER; SANCHIS, PABLO; VALACCO, MARIA PIA; GUERON, GERALDINE; BIZZOTTO, JUAN; LAGE-VICKERS, SOFÍA; VAZQUEZ, ELBA

Mar del Plata

Congreso; Reunión anual de sociedades de biociencias; 2022

Sociedad Argentina de Investigación Clínica

Prostate cancer (PCa) is a progressive disease involving multiple molecular alterations. Some PCas that are histopathologically classified as intermediate risk can differ significantly in outcome. The aim of this study was to identify molecular biomarkers that could behave independently from the commonly used PCa histopathological grading, to improve risk prediction of PCa.An in-depth proteomic analysis (LC/ESI-MS/MS) was performed on human prostate adenocarcinoma and benign prostate hyperplasia (BPH) tissues. Results rendered 89 PCa enriched proteins compared with BPH. These proteins were further evaluated in-silico using a custom-made pipeline. For this purpose, differential expression analysis was performed using 12 publicly available transcriptomic PCa datasets (n=2.668). A Shiny-based R tool was then built to allow visualization across multiple datasets. Results depicted 58 candidate proteins highly expressed across PCa datasets. Multivariable survival analyses were then performed using clinicopathological parameters as covariates including histological grading and TMPRSS2-ERG fusion status. Of note, CRIP2 and POSTN displayed significant association with high risk of death, independently from the other co-variates across multiple PCa datasets (p